<DOC>
	<DOC>NCT00097825</DOC>
	<brief_summary>The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.</brief_summary>
	<brief_title>Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Male, 2585 years old Current users of bisphosphonates such as Aredia® (pamidronate), Didronel® (etidronate), Fosamax® (alendronate), Actonel ® (residronate), Skelid® (tiludronate) History of severe liver, kidney or eye disease Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Male Osteoporosis</keyword>
</DOC>